tetano
Editor, Senior Moderator
Rev Med Virol
. 2022 Feb 10;e2329.
doi: 10.1002/rmv.2329. Online ahead of print.
Systematic review of the efficacy, effectiveness and safety of MF59 [SUP]®[/SUP] adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age
Eamon O Murchu[SUP] 1 2 [/SUP], Laura Comber[SUP] 1 [/SUP], Karen Jordan[SUP] 1 [/SUP], Sarah Hawkshaw[SUP] 1 [/SUP], Liam Marshall[SUP] 1 [/SUP], Michelle O'Neill[SUP] 1 [/SUP], Máirín Ryan[SUP] 1 3 [/SUP], Conor Teljeur[SUP] 1 [/SUP], Annasara Carnahan[SUP] 4 [/SUP], Jaime Jesús Pérez[SUP] 5 [/SUP], Anna Hayman Robertson[SUP] 6 [/SUP], Kari Johansen[SUP] 7 [/SUP], Jorgen de Jonge[SUP] 8 [/SUP], Tyra Krause[SUP] 9 [/SUP], Nathalie Nicolay[SUP] 7 [/SUP], Hanna Nohynek[SUP] 10 [/SUP], Ioanna Pavlopoulou[SUP] 11 12 [/SUP], Richard Pebody[SUP] 13 [/SUP], Pasi Penttinen[SUP] 7 [/SUP], Marta Soler-Soneira[SUP] 14 [/SUP], Ole Wichmann[SUP] 15 [/SUP], Patricia Harrington[SUP] 1 [/SUP]
Affiliations
Abstract
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59[SUP]®[/SUP] adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59[SUP]®[/SUP] adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were effective in preventing laboratory-confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%-61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%-73%) and B (VE = 29%, 95% CI 5%-46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59[SUP]®[/SUP] adjuvanted trivalent vaccines with either non-adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50-2.39) and systemic reactions (RR = 1.18, 95% CI 1.02-1.38). In conclusion, MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were found to be more effective than 'no vaccination'. Based on limited data, there was no significant difference comparing the effectiveness of MF59[SUP]®[/SUP] adjuvanted vaccines with their non-adjuvanted counterparts.
Keywords: Fluad; MF59; influenza vaccines.
. 2022 Feb 10;e2329.
doi: 10.1002/rmv.2329. Online ahead of print.
Systematic review of the efficacy, effectiveness and safety of MF59 [SUP]®[/SUP] adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age
Eamon O Murchu[SUP] 1 2 [/SUP], Laura Comber[SUP] 1 [/SUP], Karen Jordan[SUP] 1 [/SUP], Sarah Hawkshaw[SUP] 1 [/SUP], Liam Marshall[SUP] 1 [/SUP], Michelle O'Neill[SUP] 1 [/SUP], Máirín Ryan[SUP] 1 3 [/SUP], Conor Teljeur[SUP] 1 [/SUP], Annasara Carnahan[SUP] 4 [/SUP], Jaime Jesús Pérez[SUP] 5 [/SUP], Anna Hayman Robertson[SUP] 6 [/SUP], Kari Johansen[SUP] 7 [/SUP], Jorgen de Jonge[SUP] 8 [/SUP], Tyra Krause[SUP] 9 [/SUP], Nathalie Nicolay[SUP] 7 [/SUP], Hanna Nohynek[SUP] 10 [/SUP], Ioanna Pavlopoulou[SUP] 11 12 [/SUP], Richard Pebody[SUP] 13 [/SUP], Pasi Penttinen[SUP] 7 [/SUP], Marta Soler-Soneira[SUP] 14 [/SUP], Ole Wichmann[SUP] 15 [/SUP], Patricia Harrington[SUP] 1 [/SUP]
Affiliations
- PMID: 35142401
- DOI: 10.1002/rmv.2329
Abstract
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59[SUP]®[/SUP] adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59[SUP]®[/SUP] adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were effective in preventing laboratory-confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%-61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%-73%) and B (VE = 29%, 95% CI 5%-46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59[SUP]®[/SUP] adjuvanted trivalent vaccines with either non-adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50-2.39) and systemic reactions (RR = 1.18, 95% CI 1.02-1.38). In conclusion, MF59[SUP]®[/SUP] adjuvanted trivalent influenza vaccines were found to be more effective than 'no vaccination'. Based on limited data, there was no significant difference comparing the effectiveness of MF59[SUP]®[/SUP] adjuvanted vaccines with their non-adjuvanted counterparts.
Keywords: Fluad; MF59; influenza vaccines.